Abbott to Acquire Jomed's Vascular Line

In a move that will expand the company's vascular device business, Abbott Laboratories (Abbott Park, IL, USA) has agreed to acquire the coronary and peripheral interventional business line of the Jomed group (Helsingborg, Sweden) for 60 million euros in cash. The purchase covers products, intellectual property, equipment, facilities, and employees associated with the business line.

Through the agreement, Abbott will gain access to Jomed's broad line of interventional cardiology and peripheral devices. These include stents, stent grafts, balloon devices, and guiding and diagnostic catheters used in the treatment of arterial obstructions in the coronary arteries, lower extremities, kidneys, and carotid arteries. Jomed's international sales force will continue to market the current and future products of Abbott Vascular Devices (Redwood City, CA, USA), the cardiovascular device franchise of Abbott Laboratories.

"This asset purchase is an excellent fit with our strategy to build an expansive portfolio of vascular products,” said Robert B. Hance, vice president, vascular devices, Hospital Products, Abbott Laboratories. "Specifically, this will enhance Abbott's global research and development, manufacturing, and commercial capabilities in the cardiovascular devices arena.”





Related Links:
Abbott
Jomed